A family office based in USA looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers company that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.
The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.
The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Family Office Firm Most Interested in Early-Stage Medical Device and Diagnostics Companies Located in North America
24 FebHot Investor Mandate: Life Science-Focused VC Seeks to Invest $5 to 25M in Therapeutics & Medical Device Companies in Oncology, Immunology, CNS Indications, and More
24 FebA life sciences venture capital fund based in Hong Kong currently manages three funds and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.
The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology, metabolic and CNS diseases, but is also focused on new modalities and platform technologies. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.
The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Last Day to Save at Digital RESI March 2022
17 FebBy Antoinette Lowre, Manager of Business Development, LSN
Tomorrow is the final day to save! On Friday, February 18, Digital RESI March early bird rates come to an end, making it the last day to save $200 on registration.
The Redefining Early Stage Investments (RESI) conference series connects startups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development over three days. RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare. Register here to sign up and save!
In addition to one-to-one meetings, one of our most popular events is the Innovator’s Pitch Challenge (IPC). The IPC is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Applications are open and accepted on a rolling basis, so get yours in today!
To learn more about Digital RESI March check out our brochure! We hope to see you there!
Help! How to Connect When an Investor Won’t Respond
17 FebBy Karen Deyo, Director of Investor Research, Israel BD, LSN
Life Science Nation (LSN) is well-known for teaching startup founders how to identify fit, reach out, and follow up with early-stage investors, but a prominent issue remaining is this: What happens when the message is clear, the materials are strong, the fit is promising, but you cannot get a response? What happens when an investor ghosts you?
Let’s go back to the beginning: No outreach campaign should consist of just one message. When working with our clients, we always recommend crafting a four-part outreach plan. The first message, which should be your elevator pitch, should be followed by several other messages, each highlighting a different part of the company that makes you unique. Whether this is the management team, a KOL in your advisory board, a strategic partnership that will help your technology enter the market – the messages will depend on what makes your company unique. Make sure to wait a decent interval between your outreach attempts, as you do not want the investors to feel that you are overloading them with messages. Also, do not take the lack of response personally. Many investors liken their inboxes to ‘drinking out of a firehose’ with the sheer number of inbound messages they receive from startups, and they may have just missed the first message.
If you find yourself consistently getting either no or negative feedback, you may need to adjust your messaging. A service, like LSN’s Branding and Messaging, can help craft a message that will resonate. You may also have connections with investors who can help identify what should be adjusted for a better response. One company at a past RESI crafted multiple messages and tried them all just to see which got him the best result. Once he saw which message garnered the most attention, he went forward with that for the rest of his outreach and ended up with an extremely successful conference, with many connections made. When fundraising outside the context of a conference, we recommend waiting with your top-tier targets, specifically to allow you to adjust your messaging to improve the response.
Another way companies can make themselves stand out is by putting in the effort to customize their messages for the investor. Say why you think it is a good fit for them, based on their investment criteria, or mention a specific portfolio company that made you think you would be a good fit for them. Investors can tell when you exert special effort to catch their attention specifically, and that can make them pay more attention to you in turn. While this makes the outreach stage a lot more labor-intensive, the outcome can be worth the effort.
Lastly, be creative in your outreach strategy. Doing an email campaign or requesting a meeting at a partnering conference are obvious choices, but in addition to these, you can find alternative paths to an initial meeting. Social media platforms like LinkedIn can be extremely useful for this – Look for the investor you are trying to reach and see if any unexpected connections pop up that you can utilize to make an introduction. If, when looking through the investor’s portfolio companies, you find one that you know, they may be willing to connect you, as well. Business connections do not always start through an introduction by someone you know extremely well, sometimes an acquaintance will make the connection that matters most – So keep your mind open and keep trying until you succeed!
While these tips can help limit the chance of having messages missed or ignored by investors, there is no fool-proof way to ensure that does not happen to you. It is an inevitability that some messages may go unread or unanswered, even from an investor who seemed initially interested. In this case, your best course of action is to follow the outreach plan outlined above. Trying to understand why or reading into a crystal ball may not be the best use of your time. It is an unfortunate part of the process, which is why fundraising is a numbers game and you increase your odds with every message. Remember that it is not personal, and so long as you are crafting a compelling message with a strong story to the right people, you are heading in the right direction.
Want to learn more? Join us at a free bootcamp: Strategies for Successful Partnering on Tuesday, March 8 at 12PM EST. This bootcamp covers tactical fundraising skills for early-stage companies on how to build a target investor list to prepare investor meetings. Sign up today and learn more about LSN partnering events like Digital RESI, March 22-24. Early bird registration rates end Friday, February 18.
Hot Investor Mandate: Life Science Investment Arm of Global PE Firm Invests Up to $20M in Clinical-Stage Therapeutics, Medical Devices, and Diagnostics
17 FebThe life science investment arm of a global private equity firm with multi-billion dollars in assets under management has offices across the USA. The fund may invest a total of up to $20 million per portfolio company across multiple financing rounds, and may be a lead investor or a co-investor. The firm is interested in life science opportunities worldwide. The PE firm also has a separate investment arm that invests in early growth companies in the medical device, healthcare IT and diagnostics sectors.
The firm invests in therapeutics, medical devices and diagnostics. For therapeutic investments, the fund generally looks for clinical proof of efficacy in Phase Ib or IIa trials. For PMA medical devices, the firm also requires clinical proof of efficacy data. For 510k devices and diagnostics, the firm makes growth equity investments in companies that have approved products and are in early commercialization. It is required that diagnostics have reimbursement codes. The firm will consider investments in any indication or technology area.
The growth-stage investment arm invests in digital health, medtech and diagnostics companies with revenue streams, and uses a variety of structures to provide credit or royalty financing to early growth stage companies.
The firm invests in both experienced management teams, as well as new entrepreneurs. The firm is open to investing in both privately-held and public companies. If a management team is incomplete or inexperienced, The firm is open to working to fill or change the team.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Private Investment Firm Seeks Opportunities in Therapeutics, Diagnostics, Synthetic Biology, and Other Groundbreaking Technology
17 FebA private investment firm based in West Coast USA invests across all stages, from company formation through IPO. As an evergreen fund, the firm has invested in big name biotech companies, and is capable of making large investments with no set limit.
The firm is primarily focused on 3 areas: (1) therapeutics, (2) diagnostics, and (3) synthetic biology, but open to other sectors with groundbreaking technology.
The firm has a flexible mandate and does not have any specific company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Newly Founded USA-Based VC Firm Invests in Early-Stage Biotech, Digital Health, Medtech, and More, Open to Companies Outside of the USA
17 FebA newly established venture capital firm based in the USA is actively seeking early-stage investment opportunities in life sciences and healthcare sectors with its first fund. The firm is focused on emerging companies in pre-seed / seed rounds and will participate in Series A at the maximum. Currently, the firm is focused on USA-based companies, but can dedicate a portion of their fund to invest outside of the USA.
The firm invests in 4 main focus areas, ordered by priority: (1) biotech, which includes biomarkers, liquid biopsies, cell therapy, smart packaging, drug delivery, next generation sequencing, omics; (2) digital health, which includes wearables, diagnostics, services, AI-enabled approaches, management, fitness, digital therapy; (3) medtech, which includes smart devices, smart lens, breath biopsy, 3D printing, in vitro diagnostics, surgical robotics, laser therapy; (4) health edtech, which includes personalized learning, med. professional development, immersive learnings (e.g., VR), wellness. The firm plans to expand their investment capabilities in medtech, as they have recently made great investments in this space. The firm is indication agnostic, and is open to all opportunities including oncology, cardiovascular, infectious, metabolic, neurological, and rare/orphan diseases.
The firm seeks to work with companies backed by a management team with deep domain expertise and technologies that are backed by solid IP. The firm prefers to act as a follow-on, but will seek to lead more investment rounds in the future.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 